Bhatia, S., Gooley, T., Brohl, A. S., Fecher, L. A., Chandra, S., Gao, L., Silk, A. W., Medina, T., Moschos, S. J., Chen, W., Hibbert, R., Dakhil, S., Kiriluk, S., Voutsinas, J. M., Nghiem, P., Tykodi, S. S., Kelly, C. M. (2026). ADAM trial: A multicenter, randomized, double-blinded, placebo-controlled, phase 3 trial of adjuvant avelumab (anti-PD-L1 antibody) in patients with Merkel cell carcinoma and lymph node metastases.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.17_suppl.lba9504